BLPH News and Press, Bellerophon Therapeutics Inc. From 02/23/20

Amarin Looks Promising Ahead of Full Year Results, Receives Upgrade Amarin ( AMRN ) received a boost when Citigroup upgraded its stock to Buy. The target price for the stock has been set at $24 a share, showing considerable upside from the current market price, but still below its recent h...

Gainers: Bellerophon Therapeutics (NASDAQ: BLPH )  +144% . More news on: Bellerophon Therapeutics, Inc., Brickell Biotech, Inc., Wanda Sports Group Company Limited, Stocks on the move, , Read more ...

Bellerophon Therapeutics (NASDAQ: BLPH ) +67%  on positive top-line data from a recently completed acute, intra-patient, dose escalation, hemodynamics study of INOpulse for the treatment of Pulmonary Hypertension associated with Pulmonary Fibrosis. More news on: Bellerophon Therape...

Thinly traded nano cap Bellerophon Therapeutics (NASDAQ: BLPH ) jumps  61%  premarket on robust volume in reaction to positive topline data from a 16-subject Phase 2 clinical trial, PULSE-PHPF-002 , evaluating INOpulse in patients with pulmonary hypertension associated with pulm...

WARREN, N.J., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive top-line data from a recently completed acute, intra-patient, dose e...

WARREN, N.J., Feb. 07, 2020 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced the filing of a certificate of amendment to its amended and restated certific...

Bellerophon Therapeutics (NASDAQ: BLPH ) is up  36%  on the heels of positive top-line results from Cohort 2 of its ongoing Phase 2/3 study (iNO-PF) of INOpulse for the treatment of Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD). More news on: Bellero...

Statistically Significant Improvement Demonstrated in Moderate to Vigorous Physical Activity Bellerophon Intends to Initiate Pivotal Phase 3 in First Quarter of 2020 Company Enters Into $10M Convertible Financing Facility Led By Existing Institutional Shareholders, Extending Cas...

WARREN, N.J., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced positive initial data from an acute, dose escalation, clinical study (PHPF-00...

WARREN, N.J., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, is presenting data from Cohort 1 of its ongoing Phase 2/3 randomized, double-blind, placebo-c...